Table 2.
Results
| Patient number | Initial total tumor volume/perfused volume (cc) | Immediate posttreatment total volume/perfused volume (cc) | Followup (months) | Total volume/perfused volume at most recent followup (cc) | Percent decrease in perfused volume compared with the initial size | Treatment time including positioning and preparation (minutes) | MSTS score before treatment/most recent followup | Complications |
|---|---|---|---|---|---|---|---|---|
| 1 | 1010/1010 | 1010/334 | 12 | 248/0 | 100% | 410 | NA | Asymptomatic lipase elevation |
| 2 | 157/157 | 157/82 | 15 | 98/27 | 67% | 265 | 16/16 (patient has cerebral palsy) | Blister, partial nerve injury |
| 3 | 98/98 | 98/25 | 23 | 5/4 | 84% | 267 | 15/17 | Gluteal muscle MR signal change, mild skin erythema |
| 4 | 142/142 | 142/53 | 21 | 227/121 | 15% | 234 | 27/27 | Temporary pain |
| 5 | 42/42 | 42/16 | 20 | 29/17 | 60% | 175 | 27/29 | Blister |
MSTS = Musculoskeletal Tumor Society; NA = not available.